<?xml version='1.0' encoding='utf-8'?>
<document id="31416331"><sentence text="A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy."><entity charOffset="89-101" id="DDI-PubMed.31416331.s1.e0" text="Methotrexate" /><entity charOffset="115-127" id="DDI-PubMed.31416331.s1.e1" text="Methotrexate" /><pair ddi="false" e1="DDI-PubMed.31416331.s1.e0" e2="DDI-PubMed.31416331.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31416331.s1.e0" e2="DDI-PubMed.31416331.s1.e1" /></sentence><sentence text="Background: High-dose methotrexate (HD-MTX) therapy is widely implemented for leukemia, osteosarcoma, and lymphoma"><entity charOffset="22-34" id="DDI-PubMed.31416331.s2.e0" text="methotrexate" /><entity charOffset="36-42" id="DDI-PubMed.31416331.s2.e1" text="HD-MTX" /><pair ddi="false" e1="DDI-PubMed.31416331.s2.e0" e2="DDI-PubMed.31416331.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31416331.s2.e0" e2="DDI-PubMed.31416331.s2.e1" /></sentence><sentence text=" Although various measures have been taken to avoid toxicity from high serum MTX concentrations, there are many cases of delayed elimination of MTX" /><sentence text=" Objective: We suspected that delayed elimination of serum MTX was caused by unknown interactions between MTX and concomitant drugs" /><sentence text=" Methods: Concerning concomitant drugs in the case of delayed elimination of MTX, we performed screening tests in 35 patients who had undergone HD-MTX therapy" /><sentence text=" We then investigated the risk factors for delayed MTX elimination in 94 patients with leukemia, lymphoma, or osteosarcoma retrospectively" /><sentence text=" Results: The percentages of concomitant use of Stronger Neo-Minophagen C (SNMC), a glycyrrhizin preparation, and vincristine were higher in the delayed group"><entity charOffset="57-73" id="DDI-PubMed.31416331.s7.e0" text="Neo-Minophagen C" /><entity charOffset="84-96" id="DDI-PubMed.31416331.s7.e1" text="glycyrrhizin" /><entity charOffset="114-125" id="DDI-PubMed.31416331.s7.e2" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.31416331.s7.e0" e2="DDI-PubMed.31416331.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31416331.s7.e0" e2="DDI-PubMed.31416331.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31416331.s7.e0" e2="DDI-PubMed.31416331.s7.e2" /><pair ddi="false" e1="DDI-PubMed.31416331.s7.e1" e2="DDI-PubMed.31416331.s7.e1" /><pair ddi="false" e1="DDI-PubMed.31416331.s7.e1" e2="DDI-PubMed.31416331.s7.e2" /></sentence><sentence text=" The percentage of delayed MTX elimination in patients receiving HD-MTX therapy was 41%" /><sentence text=" Multiple logistic regression analysis revealed that the concomitant use of SNMC solely was a significant risk factor for delayed MTX (odds ratio = 12"><entity charOffset="130-133" id="DDI-PubMed.31416331.s9.e0" text="MTX" /></sentence><sentence text="20; 95% CI = 1" /><sentence text="06-139" /><sentence text="84)" /><sentence text=" Conclusion and Relevance: Concomitant use of SNMC was shown to be related to delayed elimination of serum MTX, and our results suggested a previously unknown drug-drug interaction between MTX and SNMC"><entity charOffset="107-110" id="DDI-PubMed.31416331.s13.e0" text="MTX" /><entity charOffset="189-191" id="DDI-PubMed.31416331.s13.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.31416331.s13.e0" e2="DDI-PubMed.31416331.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31416331.s13.e0" e2="DDI-PubMed.31416331.s13.e1" /></sentence><sentence text="" /></document>